FDA inspection
Mayinglong Pharmaceutical Group Co., Ltd.: FDA inspection ending Apr 13, 2018
FDA inspection 1051249 · Voluntary Action Indicated (VAI) · Wuhan
Key facts
| Inspection ID | 1051249 |
|---|---|
| Firm | Mayinglong Pharmaceutical Group Co., Ltd. |
| FEI number | 3004363818 |
| Address | 100 Zhoujiawan |
| City | Wuhan |
| Country | China |
| Fiscal year | 2018 |
| Inspection end date | Apr 13, 2018 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data